Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection

Journal of Infectious Diseases

Volumn 167, Issue 2, 1993, Pages 291-298

  Teppler, Hedy ^a,b   Kaplan, Gilla ^a,b   Smith, Kendall ^a,b   Cameron, Paul ^a,b   Montana, Antonia ^a,b   Meyn, Peter ^a,b   Cohn, Zanvil ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MACROGOL;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN BIOPSY; VIRUS CULTURE;

ADULT; HIV INFECTIONS; HIV-1; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; INJECTIONS, INTRADERMAL; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGE; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ZIDOVUDINE;

EID: 0027393393     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/167.2.291     Document Type: Article

References (50)

1. Stahl RE, Friedman-Kien A, Dubin R, Marmor M, Zolla-Pazner S. Immunologic abnormalities in homosexual men. Am J Med 1982;73:171-8.
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;230:868-71.
3. Gallo RC, Salah uddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
4. Klatzman D, Barre-Sinoussi F, Nugeyre MT, et al. Selective tropism of lymphadenopathy associated virus (LA V) for helper-inducer T lymphocytes. Science 1984;225:59-63.
5. Bowen DL, Lane HC, Fauci AS. Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:704-9.
6. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection ofCD4+ memory T cells by human immunodeficiency virus type I: Evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990;87:6058-62.
7. Murray HW, Welte K, Jacobs JL, Rubin BY, Mertelsmann R, Roberts RB. Production of and in vitro response to interleukin-2 in the acquired immunodeficiency syndrome. J Clin Invest 1985;76: 1959-64.
8. Murray HW, Rubin BY, Masur H, Roberts RB. Impaired production of Iymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:883-9.
9. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
10. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991;324: 1644-50.
11. Centers for Disease Control. Nosocomial transmission of multi-drug-resistant tuberculosis among HIV-infected persons in Florida and New York, 1988-1991. MMWR 1991;40:585-91.
12. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus-an analysis using restriction fragment length polymorphisms. N Engl J Med 1992;326:231-5.
13. Bratt G, von Krogh G, Moberg L, et al. Intradermal testing with multiple recall antigens for identification of cell-mediated immune deficiency in homosexual men. Clin Immunol Immunopathol 1986;41:206-15.
14. Lane HE, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;313:7984.
15. Miedema F, Chantal Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. J Clin Invest 1988;82: 1908-14.
16. Smith KA. Interleukin-2: Inception, impact and implications. Science 1988;240: 1169-76.
17. McElrath MJ, Kaplan G, Burkhardt R, Cohn ZA. Cutaneous response to recombinant interleukin-2 in human immunodeficiency virus l-seropositive individuals. Proc Natl Acad Sci USA 1990;87:5783-7.
18. Kaplan G, Kiessling R, Teklemariam S, et al. The reconstitution of cell-mediated immunity in the cutaneous lesion of lepromatous leprosy by recombinant interleukin-2. J Exp Med 1989; 169:893-907.
19. Converse P, Ottenoff THM, Teklemariam S, et al. Intradermal recombinant interleukin-2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Scand J Immunol 1990;32:83-91.
20. Hancock GE, Cohn ZA, Kaplan G. The generation ofantigen-specific, major histocompatibility complex-restricted T lymphocytes of the CD4+ phenotype. J Exp Med 1989; 169:909-19.
21. Hancock GE, Molloy A, Ab BK, et al. In vivo administration of lowdose human interleukin-2 induces Iymphokine activated killer cells for enhanced cytolysis in vitro. Cell Immunol 1991; 132:277-84.
22. Centers for Disease Control. Classification system for human T-Iymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 1986;35:334-9.
23. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl IS):3S-15S.
24. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223: 1412-5.
25. Kaplan G, Weinstein DE, Steinman RM, et al. An analysis of in vitro T cell responsiveness in lepromatous leprosy. J Exp Med 1985; 162:917-29.
26. Teppler H, Lee SH, Reiber EP, Gordon S. Murine immunoglobulin G anti-CD4 monoclonal antibodies bind to primary human monocytes and macrophages through Fe receptors as well as authentic CD4. AIDS 1990;4:627-32.
27. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH Jr. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol 1988;26: 1416-8.
28. Ho DO, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type I in the blood of infected persons. N Engl J Med 1989;321: 1621-5.
29. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321: 1626-31.
30. McLean IW, Nakane PK. Periodate-Iysine-paraformaldehyde fixative, a new fixture for immunoelectron microscopy. J Histochem Cytochern 1974;22: 1077-83.
31. Kaplan G, Laal S, Sheftel G, et al. The nature and kinetics ofa delayed immune response to purified protein derivative of tuberculin in the skin oflepromatous leprosy patients. J Exp Med 1988; 168: 1811-24.
32. Kaplan G, Luster AD, Hancock G, Cohn ZA. The expression of a gamma interferon-induced protein (IP-IO) in delayed immune responses in human skin. J Exp Med 1987;166:1098-108.
33. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol 1986;38: 161-77.
34. Landay A, Ohlsson-Wilhelm B, Giorgi JV. Application offlow cytometry to the study of HIV infection. AIDS 1990;4:479-97.
35. Kaplan G, Britton WJ, Hancock GE, et al. The systemic influence of recombinant interleukin-2 on the manifestations oflepromatous leprosy. J Exp Med 1991;173:993-1006.
36. Schwartz DH, Skowron G, Merigan TC. Safety and effects ofinterleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:11-23.
37. Schwartz DH, Merigan TC. Interleukin-2 in the treatment ofHIV disease. Biotherapy 1990;2: 119-36.
38. Caligiuri MA, Murray C, Soiffer RJ, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9:2110-9.
39. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo following porlonged infusion of low-dose recombinant interleukin-2. J Clin Invest (in press).
40. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
41. Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin-2 enhancesthe natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985; 134: 1503-7.
42. Bonavida B, Katz J, Gottlieb M. Mechanisms of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Immunol 1986; 137: 1157-63.
43. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon I. J Exp Med 1982; 155: 1823-41.
44. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon II. J Exp Med 1983; 157:884-97.
45. Brenner BG, Dascal A, Margolese RG, Wainberg MA. Natural kilIer cell function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc BioI 1989;45:75-83.
46. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
47. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320: 1731-5.
48. Ruscetti FW, Mikovits IA, Kalyanaraman VS, et al. Analysis ofeffector mechanisms against HTLV-I and HTLV-III/LAV infected lymphoid cells. J Immunol 1986; 136:3619-24.
49. Weinhold KJ, Matthews TI, Ahearne PM, et al. CelIular anti-gpl20 cytolytic reactivities in HIV-I seropositive individuals. Lancet 1988; I:902-5.
50. Tyler OS, Nastala CL, Stanley SO, et al. gp 120 specific cellular cytotoxicity in HIV-I seropositive individuals. J Immunol 1989; 142: 117-782.